15,018 Shares in Moderna, Inc. $MRNA Bought by Sanctuary Advisors LLC

Sanctuary Advisors LLC acquired a new stake in Moderna, Inc. (NASDAQ:MRNA) in the 2nd quarter, Holdings Channel reports. The fund acquired 15,018 shares of the company’s stock, valued at approximately $1,052,000.

Several other hedge funds also recently made changes to their positions in MRNA. BlackRock Inc. purchased a new stake in shares of Moderna in the 2nd quarter valued at about $2,142,877,000. Capital World Investors acquired a new position in Moderna during the fourth quarter worth approximately $378,299,000. Alyeska Investment Group L.P. acquired a new position in Moderna during the fourth quarter worth approximately $95,209,000. Norges Bank purchased a new stake in Moderna in the fourth quarter valued at approximately $79,707,000. Finally, Merck & Co. Inc. purchased a new stake in Moderna in the second quarter valued at approximately $161,642,545,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on MRNA. JPMorgan Chase & Co. increased their price objective on Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a report on Friday, August 21st. Piper Sandler reiterated an “overweight” rating on shares of Moderna in a research report on Monday, August 3rd. Wolfe Research upgraded shares of Moderna from an “underperform” rating to a “peer perform” rating in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Moderna in a research report on Friday, June 12th. Finally, UBS Group raised their price objective on shares of Moderna from $50.00 to $150.00 and gave the stock a “neutral” rating in a research report on Thursday, August 20th. Four investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and a consensus target price of $74.31.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: The FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, which target the XFG subvariant. The approval supports Moderna’s ability to participate in the upcoming seasonal vaccination market, although Spikevax eligibility is focused on adults 65 and older and higher-risk people ages 6 months through 64. FDA approves updated COVID vaccines
• Positive Sentiment: Renewed attention on Moderna and Merck’s personalized cancer vaccine, intismeran, is supporting the company’s long-term oncology story. Reports indicate the therapy reduced melanoma recurrence by approximately 49% in a late-stage study, strengthening expectations that Moderna could diversify beyond its declining COVID-19 business. Personalized melanoma vaccine results
• Neutral Sentiment: Moderna announced plans to raise $2 billion through convertible senior notes due in 2032, with an option for purchasers to increase the deal to $2.3 billion. Proceeds may fund oncology investments and debt repayment, while a hedge overlay is intended to offset dilution up to a specified cap. Moderna convertible notes offering
• Negative Sentiment: Investors are reacting cautiously to the financing because convertible notes can create future share dilution and signal substantial funding needs. The offering comes while Moderna remains unprofitable, making the company’s elevated valuation more difficult to justify on current earnings and revenue. Moderna borrows $2 billion

Moderna Stock Down 4.6%

Moderna stock opened at $142.77 on Friday. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $176.66. The stock has a 50 day moving average of $75.62 and a two-hundred day moving average of $59.17. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $57.00 billion, a price-to-earnings ratio of -17.87 and a beta of 0.91.

Moderna (NASDAQ:MRNA) last announced its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $0.06. The company had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The company’s revenue was up 2.1% on a year-over-year basis. During the same period last year, the business posted ($2.13) EPS. As a group, research analysts expect that Moderna, Inc. will post -6.18 earnings per share for the current year.

Insider Buying and Selling at Moderna

In related news, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the transaction, the insider directly owned 67,468 shares in the company, valued at $3,373,400. This trade represents a 4.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction on Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.80% of the stock is owned by company insiders.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.